Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Autonomous Technology & Robotics ETF (ARKQ) vs Cassava Sciences Inc (FLNA) Price & Performance

ARK Autonomous Technology & Robotics ETF
Cassava Sciences Inc

Price performance

Price movement over the last 24 hours

Key statistics

ARK Autonomous Technology & Robotics ETF vs Cassava Sciences Inc — how do they compare? ARK Autonomous Technology & Robotics ETF trades at $123.27, while Cassava Sciences Inc trades at $1.18 (market cap $57.49M). The key difference: ARK Autonomous Technology & Robotics ETF is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals.

ARKQFLNA
Sector
Sector/ThematicHealth
52-Week High
$143.82$4.64
52-Week Low
$91.86$1.16
Market Cap
$57.49M
Enterprise Value
-$29.09M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Autonomous Technology & Robotics ETF

ARKQ trades at $123.99, down 0.57% with a bearish technical signal from moving averages. The ETF focuses on autonomous technology and robotics, benefiting from AI momentum with 57% gains since Q1 2026. Support levels cluster around $122-124 while resistance sits at $126-128. Recent news highlights China's EV targets and humanoid robotics growth projections reaching $200 billion by 2035.

The ETF shows strong momentum in AI and robotics themes but carries premium valuations with a 36x P/E ratio. Key risks include sector concentration and dependency on technological adoption rates. Institutional interest remains strong with $2.7 billion in assets, though technical indicators suggest near-term consolidation pressure.

Cassava Sciences Inc

FLNA trades at $1.18, down 0.84% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -79.59% and ROA at -62.5%, though it has beaten EPS estimates for three consecutive quarters. Recent news highlights Q1 2026 financial results and scientific presentations on TSC-related epilepsy therapies. Analyst consensus remains positive with 67% buy ratings.

While analyst sentiment is bullish, FLNA faces significant fundamental challenges with negative cash flow and earnings. The primary investment opportunity lies in successful drug development, but risks include sustained cash burn and clinical trial outcomes. Investors should weigh the high-risk biotech profile against potential pipeline catalysts.

Returns comparison

Trailing returns across standard periods

About ARK Autonomous Technology & Robotics ETF

ARKQ is an actively managed ETF that invests in autonomous technology and robotics. It focuses on disruptive innovations like autonomous mobility, electric vehicles, 3D printing, and energy storage, with holdings such as Tesla and Teradyne.

Read more on ARKQ

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA